Project Description
Follow-On Offering
Common Stock
.
$125,000,000
Co-Manager
April 2021
Aldeyra Therapeuticsdan2023-12-15T00:57:18-05:00
Aldeyra Therapeuticsdan2023-12-15T00:57:18-05:00
Aldeyra Therapeuticsdan2023-12-15T00:57:18-05:00
Aldeyra Therapeuticsdan2023-12-15T00:57:18-05:00
Site Info
Contact Info
© 2024 Copyright Laidlaw & Company (UK) Ltd. – All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through StoneX, a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).
© Copyright 2021 Laidlaw & Company (UK) Ltd. - All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through INTL FCStone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).
Stay In Touch